Spotlight on Uncontrolled Hypertension: Assessing the Shift Towards Personalised Medicine – Part 2
Gain expert insights into the personalised management of uncontrolled hypertension, with a focus on real-world evidence and emerging therapeutic strategies. Join Dr Sophia Ambruso (University of Colorado, Denver, US) and Prof Paolo Mulatero (University of Turin, Turin, IT) as they explore the role of aldosterone dysregulation, the impact of cardiorenal outcomes and the limitations of current treatments. The session also highlights novel treatment approaches such as nonsteroidal MRAs, endothelin receptor antagonists and aldosterone synthase inhibitors (ASIs).
Learning Objectives
- Assess cardiovascular risks of uncontrolled hypertension
- Understand pathophysiology with a focus on aldosterone’s role
- Examine novel therapeutic targets
Target Audience
- Cardiologists
- Hypertension Specialist
- Nephrologists
- Primary Care Physicians
- Pharmacists
- Healthcare Professionals
More from this programme
Part 1
Aldosterone and Aldosterone Dysregulation
Dr Sophia Ambruso and Prof Paolo Mulatero explore the origins and physiological role of aldosterone, providing background on its discovery and examining the underlying mechanisms driving aldosterone dysregulation in clinical practice.
Part 2
Aldosterone Dysregulation
Dr Sophia Ambruso and Prof Paolo Mulatero examine the pathological consequences of aldosterone dysregulation, offering insights from both vascular and renal perspectives to highlight its impact on target organ damage.
| 1 session | |
| Watch now |
Part 3
How Are We Addressing Aldosterone Dysregulation Currently?
Dr Sophia Ambruso and Prof Paolo Mulatero discuss current strategies for managing aldosterone dysregulation and explore emerging evidence on how aldosterone synthase inhibitors (ASIs) differ from traditional mineralocorticoid receptor antagonists (MRAs), highlighting potential advantages in clinical practice.
Part 4
What Evidence Do We have for Novel ASIs?
Together, Prof Mulatero and Dr Ambruso review the current evidence surrounding aldosterone synthase inhibitors (ASIs), examining their potential advantages and clinical indications compared to mineralocorticoid receptor antagonist (MRA) therapy.
Part 5
Audience Q&A
In this session, Prof Mulatero and Dr Ambruso address audience questions, offering real-world insights into the challenges and clinical implications of aldosterone dysregulation.
| 1 session | |
| Watch now |
Faculty Biographies
Paolo Mulatero
Professor of Internal Medicine and Head of the Hypertension Unit
Prof Paolo Mulatero is Professor of Internal Medicine and Head of the Hypertension Unit, Department of Medical Sciences at the University of Turin, Turin, Italy. His main research interests include pathophysiology; clinical and molecular genetics of primary aldosteronism; biochemistry and genetics of 11b-hydroxylase and aldosterone synthase (CYP11B1 and CYP11B2) and their role in human pathologies (essential hypertension, primary aldosteronism, glucocorticoid-remediable aldosteronism, aldosterone synthase deficiency type I and II); clinical genetics of the monogenic forms of hypertension; the genetic and pathophysiology of essential and secondary hypertension and the evaluation of the cardiovascular risk factors.
Sophia Ambruso
Clinical Nephrologist and Assistant Professor
Dr Sophia Ambruso is a Clinical Nephrologist and Assistant Professor at the Rocky Mountain VA Medical Center and University of Colorado School of Medicine, Denver, US. Dr Ambruso is passionate about patient care and medical education. She is on the Executive Committee and a faculty member for the Nephrology Social Media Collective (NSMC) internship.